Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Lactate, once a metabolic byproduct, is now recognized as crucial in cancer progression and immune suppression.
• Lysine lactylation, a post-translational modification, is increasingly implicated in cellular regulation.
• Pancreatic adenocarcinomas exhibit elevated glycolysis and lactate, yet lactylation-related genes are understudied.

Purpose of the Study:

• To develop a novel gene signature based on lactylation-related genes (LRGs) for predicting survival in pancreatic cancer patients.
• To explore the role of lactylation and specific LRGs in pancreatic adenocarcinoma (PDAC) progression and immune microenvironment.

Main Methods:

• Utilized RNA-seq and clinical data from TCGA and GTEx databases for PDAC analysis.
• Constructed a prognostic model using univariate, LASSO, and multivariate Cox regression analyses.
• Validated findings through in vitro (cell line assays) and in vivo (tumor models) experiments, focusing on SLC16A1 function.

Main Results:

• Identified 10 differentially expressed LRGs with prognostic value in PDAC.
• Developed a five-gene signature (SLC16A1, HLA-DRB1, KCNN4, KIF23, HPDL) for predicting overall survival.
• Demonstrated that SLC16A1 promotes PDAC proliferation and migration via lactylation, and targeting this pathway inhibits tumor growth.

Conclusions:

• A novel lactylation-related prognostic signature effectively predicts overall survival, immune status, and treatment response in pancreatic adenocarcinoma.
• The study highlights the SLC16A1/lactylation pathway as a potential therapeutic target for pancreatic cancer.
• Findings provide new directions for antitumor immunotherapies in pancreatic adenocarcinoma.